Legend Biotech Statistics
Total Valuation
Legend Biotech has a market cap or net worth of $3.17 billion. The enterprise value is $2.59 billion.
Important Dates
The next estimated earnings date is Tuesday, March 10, 2026, before market open.
| Earnings Date | Mar 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Legend Biotech has 184.69 million shares outstanding. The number of shares has increased by 0.86% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 184.69M |
| Shares Change (YoY) | +0.86% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 0.08% |
| Owned by Institutions (%) | 44.07% |
| Float | 182.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 335.26 |
| PS Ratio | 3.47 |
| Forward PS | 2.25 |
| PB Ratio | 3.13 |
| P/TBV Ratio | 3.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.84 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.86, with a Debt / Equity ratio of 0.41.
| Current Ratio | 2.86 |
| Quick Ratio | 2.76 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.58 |
Financial Efficiency
Return on equity (ROE) is -22.53% and return on invested capital (ROIC) is -43.14%.
| Return on Equity (ROE) | -22.53% |
| Return on Assets (ROA) | -6.92% |
| Return on Invested Capital (ROIC) | -43.14% |
| Return on Capital Employed (ROCE) | -14.92% |
| Weighted Average Cost of Capital (WACC) | 4.82% |
| Revenue Per Employee | $348,427 |
| Profits Per Employee | -$91,875 |
| Employee Count | 2,609 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 29.45 |
Taxes
In the past 12 months, Legend Biotech has paid $17.21 million in taxes.
| Income Tax | 17.21M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -54.99% in the last 52 weeks. The beta is 0.13, so Legend Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | -54.99% |
| 50-Day Moving Average | 23.01 |
| 200-Day Moving Average | 31.45 |
| Relative Strength Index (RSI) | 27.30 |
| Average Volume (20 Days) | 3,158,459 |
Short Selling Information
| Short Interest | 19.40M |
| Short Previous Month | 17.77M |
| Short % of Shares Out | 20.08% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.96 |
Income Statement
In the last 12 months, Legend Biotech had revenue of $909.05 million and -$239.70 million in losses. Loss per share was -$1.30.
| Revenue | 909.05M |
| Gross Profit | 132.68M |
| Operating Income | -190.86M |
| Pretax Income | -222.49M |
| Net Income | -239.70M |
| EBITDA | -181.24M |
| EBIT | -190.86M |
| Loss Per Share | -$1.30 |
Full Income StatementBalance Sheet
The company has $992.59 million in cash and $410.24 million in debt, with a net cash position of $582.35 million or $3.15 per share.
| Cash & Cash Equivalents | 992.59M |
| Total Debt | 410.24M |
| Net Cash | 582.35M |
| Net Cash Per Share | $3.15 |
| Equity (Book Value) | 1.01B |
| Book Value Per Share | 5.48 |
| Working Capital | 808.43M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$170.07 million and capital expenditures -$18.61 million, giving a free cash flow of -$188.68 million.
| Operating Cash Flow | -170.07M |
| Capital Expenditures | -18.61M |
| Free Cash Flow | -188.68M |
| FCF Per Share | -$1.02 |
Full Cash Flow StatementMargins
Gross margin is 14.60%, with operating and profit margins of -21.00% and -26.37%.
| Gross Margin | 14.60% |
| Operating Margin | -21.00% |
| Pretax Margin | -24.48% |
| Profit Margin | -26.37% |
| EBITDA Margin | -19.94% |
| EBIT Margin | -21.00% |
| FCF Margin | n/a |
Dividends & Yields
Legend Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.86% |
| Shareholder Yield | -0.86% |
| Earnings Yield | -7.57% |
| FCF Yield | -5.96% |
Analyst Forecast
The average price target for Legend Biotech is $64.23, which is 274.52% higher than the current price. The consensus rating is "Buy".
| Price Target | $64.23 |
| Price Target Difference | 274.52% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (5Y) | 32.51% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Legend Biotech has an Altman Z-Score of 4.93 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.93 |
| Piotroski F-Score | 4 |
